Genmab — Februar 2024
-
EL, indeed. But where are all the other programs showing clinical promise?
-
So far we've seen nothing from the Biontech collab but vailed hints about synergistic effect. I can't point to a single thing in the pipeline with the potential to break through
-
but perhaps worse - there is a profound lack of phase 3 programs in the pipeline
-
again, indeed you need early stage clinical trials for that - but this is a company going on it's 24rd year, promising breakthrough R&D. And we are still only talking about 1st generation mabs.
-
Novo lægger mere end en Genmab til markedsværdien efter opkøb https://www.proinvestor.com/investornyt/1112779/novo-laegger-mere-end-en-genmab-til-markedsvaerdien-efter-opkob
-
As I recall, GEN had a stock emission first time the stock hit 1000 and diluted investors by 10%. That was almost 10 years ago and the rationale was to bolster the coffers and secure funds for investments. We've heard that song ever since, but investments have been precious few
-
Something does not add up
-
speaking of track record - GEN has a compounded RoI of 9% since IPO
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind